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Programmed cell death 5 mediates HDAC3 decay
to promote genotoxic stress response
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The inhibition of p53 activity by histone deacetylase 3 (HDAC3) has been reported, but the
precise molecular mechanism is unknown. Here we show that programmed cell death 5
(PDCD5) selectively mediates HDAC3 dissociation from p53, which induces HDAC3 cleavage
and ubiquitin-dependent proteasomal degradation. Casein kinase 2 alpha phosphorylates
PDCD5 at Ser-119 to enhance its stability and importin 13-mediated nuclear translocation of
PDCD5. Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and
HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation. Restoration of
PDCD5WT in PDCD5 / MEFs restores ET-induced HDAC3 cleavage. Reduction of both
PDCD5 and p53, but not reduction of either protein alone, signiﬁcantly enhances in vivo
tumorigenicity of AGS gastric cancer cells and correlates with poor prognosis in gastric cancer
patients. Our results deﬁne a mechanism for p53 activation via PDCD5-dependent HDAC3
decay under genotoxic stress conditions.
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D
eciphering the regulatory pathway for p53-dependent
apoptosis, which is involved in a variety of stress signals,
is important for understanding tumorigenesis and paving
the way for new cancer therapies1. In response to a broad range of
cellular stresses, p53 accumulates in the cell and thereby becomes
activated, indicating that protein abundance dictates function2. It
is generally believed that p53 protein accumulation is not due to
an enhanced transcriptional response of the cell, but rather is the
consequence of p53 protein stabilization resulting from post-
translational modiﬁcations3. Acetylation of p53 at different lysine
residues has been shown to produce a variety of effects on p53
function4. For example, acetylation-dependent p53 stabilization
was shown to antagonize the mouse double minute 2 homology
(MDM2)-mediated negative control of p53 (ref. 5). Conversely,
deacetylation of p53, either by an HDAC1-containing complex or
by the NAD-dependent histone deacetylase Sir2a, was shown to
repress p53-dependent transcriptional activation, apoptosis and
growth arrest. MDM2 was also shown to interfere with the
acetylation of p53, and subsequently promote the HDAC1-
mediated deacetylation of p53 (ref. 6). Thus, coordinated
interplay between histone acetytransferases and histone
deacetylases (HDACs) in the regulation of p53 acetylation is
believed to play a signiﬁcant role in p53-mediated apoptosis.
Recent studies highlight a connection between HDAC3
function and p53-mediated apoptosis. For instance, suppression
of HDAC3 expression, or inhibition of its activity, was found to
increase p53 stability and acetylation in human cancer cells7,8.
Moreover, HDAC3 and p53 have been shown to interact
indirectly via formation of a complex with the MAGE-A
tumour antigen, which confers resistance to chemotherapeutic
agents9. In accordance with the above ﬁnding, downregulation of
HDAC3 decreases cancer cell death in response to anticancer
drugs10. Stimuli such as osmotic stress or FAS ligand binding
trigger the caspase-7-dependent C-terminal cleavage of HDAC3
in mammalian cells, eventually leading to apoptosis induction by
modulation of HDAC3 activity11,12. Although these studies
demonstrated the potential engagement of HDAC3 in caspase-
7-dependent apoptosis, the effects of caspase-7-mediated cleavage
on HDAC3 deacetylase activity are somewhat controversial.
These ﬁndings suggest that apoptotic stimuli may alter the
function of HDAC3 via C-terminal cleavage, presumably by
leading to cellular apoptosis via activation of a pro-apoptotic
molecule such as p53. Consistent with this hypothesis, a meta-
analysis of human solid tumours showed that HDAC3 was one of
the most frequently upregulated genes in cancer cells13.
This suggests that cancer cells may resist apoptotic cell death,
at least in part, through HDAC3-mediated mechanisms.
However, detailed mechanisms underlying the role of HDAC3
in p53-mediated apoptosis have not been fully elucidated.
Programmed cell death 5 (PDCD5), also designated TFAR19
(TF-1 cell apoptosis-related gene-19), is a novel gene from TF-1
cells undergoing cytokine deprivation-induced apoptosis14. The
amino-acid sequence of PDCD5 is quite conserved among
eukaryotic species, indicating that PDCD5 has important
biological functions in multiple organisms. PDCD5 is widely
expressed in a variety of tissues, with messenger RNA (mRNA)
levels in fetal tissue being signiﬁcantly lower than that observed in
adult tissues15. Accumulating evidence indicates that expression
of PDCD5 is downregulated in human cancer patients,
speciﬁcally those affected by lung cancer, ovarian cancer, gastric
cancer and glioma, suggesting that decreased expression of
PDCD5 may be associated with the pathogenesis of human
tumours16–18. When overexpressed in cancer cell lines,
PDCD5 facilitates apoptosis triggered by genotoxic stress19,20.
PDCD5 protein is accumulated in cells undergoing apoptosis, and
translocates rapidly from the cytoplasm to the nucleus of cells21.
Recent studies also show that PDCD5 plays an important
enhancing role in TAJ/TROY-triggered paraptosis-like cell
death22. Sensitivity of HeLa cells to etoposide (ET)-induced
apoptosis is reduced by in situ electroporation of anti-PDCD5
monoclonal antibody23. More recently, PDCD5 was shown to
stabilize p53 by inhibiting p53–MDM2 interactions24. Although
PDCD5 appears to behave as a p53 cofactor, the precise
mechanisms behind PDCD5-mediated p53-dependent apoptosis
remain unclear.
In this study, we demonstrate that PDCD5 promotes genotoxic
stress-induced p53 acetylation through direct mediating dissocia-
tion of HDAC3 from p53, leading to caspase-3-dependent
HDAC3 cleavage. Furthermore, we reveal that PDCD5 is required
for p53 stabilization and cleavage of HDAC3 in vivo. Finally, we
verify the positive correlation between PDCD5 and p53 in human
gastric cancer patients and in vivo tumorigenicity of gastric
cancer cells. Our ﬁndings highlight the functional importance of
PDCD5 in genotoxic stress-induced p53 activation through its
HDAC3 decay-mediating activity.
Results
PDCD5 induces caspase-3-mediated cleavage of HDAC3. To
better understand the functional role of HDAC3 in apoptotic
signalling, we performed the yeast two-hybrid screen using
human testis, ovary and breast tissue libraries and identiﬁed 23
HDAC3-interacting proteins (Supplementary Table 1). Among
the identiﬁed proteins, PDCD5, a tumour suppressor that was
recently found to act as a pro-apoptotic factor, was particularly
interesting and thus selected for this study. Moreover, we detected
HDAC3 in an immunopuriﬁed PDCD5 complex with a high
conﬁdence using liquid chromatography–mass spectrometry
(MS)/MS analysis, suggesting an in vivo interaction between
HDAC3 and PDCD5 (Supplementary Table 2). Endogenous co-
immunoprecipitation analysis demonstrated that PDCD5 selec-
tively interacts with HDAC3 among class I HDACs. Reciprocally,
Figure 1 | PDCD5 selectively binds to and mediates caspase-3-dependent cleavage of HDAC3 at Asp-391. (a) PDCD5 is an HDAC3-associating protein
among PDCD proteins. Proteins from HCT-116 (p53þ /þ ) whole-cell lysate were immunoprecipitated and subsequently immunoblotted with the indicated
antibodies. (b) Overexpression of PDCD5 induces C-terminal cleavage of HDAC3. Cells were transfected with increasing amounts of Flag-PDCD5 plasmid.
Whole-cell lysates were immunoblotted with the indicated antibodies. Arrow indicates cleaved HDAC3. (c) Overexpression of PDCD5 selectively triggers
the cleavage of HDAC3, but not other class I HDACs. Cells were transfected with increasing amounts of PDCD plasmids. Whole-cell lysates were
immunoblotted with the indicated antibodies. Arrow indicates cleaved HDAC3. (d,e) In vivo validation of PDCD5-mediated HDAC3 cleavage at Asp-391.
HCT-116 cells were transfected with the indicated plasmids. Permeabilized cells were incubated with antibodies against HA and Flag, and then PLA probes
were added. Positive signals were analysed using confocal microscopy. Red dots display uncleaved HDAC3. Representative images of three independent
experiments are shown. (f) Inhibition of caspase-3 abrogates PDCD5-induced HDAC3 cleavage. HCT-116 cells were transfected with Flag-PDCD5 plasmid
and treated with the indicated caspase inhibitors. (g) Depletion of caspase-3 abrogates ET-induced HDAC3 cleavage. Cells were transfected with siRNAs
as indicated and treated with ET (100mM, 12 h). Whole-cell lysates were immunoblotted with the indicated antibodies. (h) PDCD5 is required for caspase-
3-dependent HDAC3 cleavage during ET treatment. Either shcontrol or stable shPDCD5-expressing HCT-116 cells was treated with ET. Whole-cell lysates
were analysed by western blotting with the indicated antibodies. Scale bar, 10mm.
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HDAC3 speciﬁcally interacted with PDCD5 among PDCD
proteins, which are known to be involved in apoptotic signalling.
These results indicate that HDAC3, among class I HDACs, is a
unique PDCD5-associating protein (Fig. 1a). Same results were
also obtained with A2780 ovarian cancer cells (Supplementary
Fig. 1a,b). Mapping analysis showed that the N-terminal domain
of PDCD5 (1–30 amino acids (a.a.)) directly interacts with the
N-terminal domain (1–106 a.a.) of HDAC3 (Supplementary
Fig. 1c,d).
The C-terminal cleavage of HDAC3 at Asp-391 was reported
to be important for cellular stress-induced apoptosis11,12.
Moreover, PDCD5 has been shown to induce apoptotic cell
death and upregulate expression of genes involved in
apoptosis20,21. Thus, we ﬁrst explored the possibility of PDCD5
involvement in C-terminal cleavage of HDAC3. Importantly,
overexpression of PDCD5, but not PDCD4 or PDCD6, selectively
induced cleavage of HDAC3, among class I HDACs, indicating
the exclusive role of PDCD5 in the C-terminal cleavage of
HDAC3 (Fig. 1b,c). To verify in vivo cleavage of HDAC3 by
PDCD5, a proximity ligation assay (PLA) was performed25 using
a double-tagged HDAC3 construct (Flag-HDAC3-HA).
Overexpression of PDCD5, but not PDCD4 or PDCD6,
efﬁciently induced the cleavage of HDAC3 (Fig. 1d). By
contrast, a point mutant with defective interaction with
HDAC3, PDCD5L6R, failed to induce HDAC3 cleavage,
suggesting that interaction with PDCD5 is required for HDAC3
cleavage (Fig. 1e, left panel and Supplementary Fig. 2). Because
Asp-391 of HDAC3 is known to be a conserved cleavage site, we
next investigated whether this site is a target for PDCD5-
mediated cleavage. As expected, PDCD5 induced the cleavage of
wild-type but not mutant HDAC3D391A (Fig. 1e, right panel).
As caspase-7 has been reported to be an executioner for
HDAC3 cleavage during osmotic stress11, we next examined
whether caspase-7 is also required for PDCD5-mediated HDAC3
cleavage. As expected, treatment with the pan-caspase inhibitor,
Z-VAD, abrogated PDCD5-mediated HDAC3 cleavage.
Unexpectedly, treatment with the caspase-3-speciﬁc inhibitor,
Z-DQMD, unexpectedly blocked PDCD5-mediated HDAC3
cleavage (Fig. 1f). Furthermore, inhibition of caspase-7 had no
effects on the HDAC3 cleavage by ET treatment (Fig. 1g;
Supplementary Fig. 3). ET treatment efﬁciently induced HDAC3
cleavage in HCT-116 (p53þ /þ ) cells; however, PDCD5
knockdown inhibited ET-induced HDAC3 cleavage, suggesting
PDCD5 mediates ET-induced HDAC3 cleavage (Fig. 1h). These
collectively demonstrated that PDCD5 induces caspase-3-
mediated HDAC3 cleavage in response to ET.
PDCD5 stabilizes p53 by inhibiting HDAC3–p53 interactions.
Given results suggesting PDCD5 is involved in caspase-
3-dependent HDAC3 cleavage, we next investigated the role of
PDCD5 in regulation of HDAC3 function. Because HDAC
activity is known to be a critical function of HDAC3 (ref. 26), we
ﬁrst assessed the change in HDAC3 activity after either
overexpression or depletion of PDCD5 in cells. An increase in
wild-type PDCD5 expression, but not mutant PDCD5L6R,
resulted in a decrease of HDAC3 histone deacetylase activity
(Fig. 2a). However, overexpression of either PDCD4 or PDCD6
had no effect on HDAC3 histone deacetylase activity
(Supplementary Fig. 4). Conversely, PDCD5 knockdown inhib-
ited ET-induced reduction of HDAC3 activity, indicating that
PDCD5 selectively mediates ET-induced effects on HDAC3
(Fig. 2b).
Next, we examined the molecular basis of PDCD5 involvement
in ET-induced HDAC3 cleavage and inhibition. ET treatment of
cells markedly increased the interaction between HDAC3 and
active caspase-3. However, knockdown of PDCD5 levels
abrogated this enhanced association (Fig. 2c). Importantly, while
ET treatment induced cytoplasmic accumulation of cleaved
HDAC3, knockdown of PDCD5 abolished this ET-induced
cleavage (Fig. 2d; Supplementary Fig. 5a). Conversely, ET
treatment of cells overexpressing wild-type PDCD5 further
enhanced the cytoplasmic accumulation of HDAC3 (Fig. 2e).
These data collectively demonstrate that ET triggers nuclear
translocation of PDCD5, which in turn induces nuclear export of
HDAC3 and caspase-3-mediated HDAC3 cleavage.
Acetylation and stability of p53 is coordinated by histone
acetytransferases and HDACs27. Among HDACs, HDAC3 was
recently shown to interact with p53 through MAGE-A9. Thus, we
hypothesized that nuclear PDCD5 induces dissociation of
HDAC3 from p53, subsequently triggering the cytoplasmic
translocation and caspase-3-dependent cleavage of HDAC3, in
turn increasing the acetylation level of p53. Results from co-
immunoprecipitation analyses showed ET treatment efﬁciently
induced the removal of HDAC3 from p53 and concomitant
association of p300 with p53. However, knockdown of PDCD5
abolished ET-induced HDAC3–p53 dissociation, and also
decreased p53 acetylation and stability (Fig. 2f; Supplementary
Fig. 5b). Intriguingly, we found that both HDAC3 and PDCD5
bind to the same region of p53 (100–170 a.a.) (Supplementary
Fig. 6). An in vitro pull-down and deacetylation assay showed
that HDAC3 directly binds to and deacetylates p53
(Supplementary Fig. 7a,b). An in vitro competition assay
demonstrated that wild-type PDCD5, but not the point mutant
PDCD5E16D that has defective interaction with p53, competitively
inhibited HDAC3 binding to p53 (Supplementary Figs 2 and 7c).
Consistently, PDCD5E16D overexpression did not affect HDAC3–
p53 interaction or HDAC3 cleavage compared with that of
PDCD5WT (Fig. 2g). Unexpectedly, MAGE-A2 knockdown in
both H1299 and HCT-116 (p53 / ) cells had negligible effect
Figure 2 | PDCD5 stabilizes p53 by inducing dissociation of the HDAC3–p53 complex and concomitantly triggering cytosolic cleavage of HDAC3.
(a) Overexpression of PDCD5 reduces the activity of HDAC3. HCT-116 cells were transfected with the indicated plasmids. Whole-cell lysates were
immunoprecipitated with anti-HDAC3 antibody, and then HDAC3 activity was measured. Error bars, s.d. (n¼ 3). *Po0.05. (b) Depletion of PDCD5
abolishes the ET-induced reduction of HDAC3 activity. Cells were transfected with the indicated siRNAs. Cells were treated with ET (100 mM, 12 h) or STS
(1mM, 12 h) and assayed for HDAC3 activity. Error bars, s.d. (n¼ 3). *Po0.05. (c) Knockdown of PDCD5 abrogates the association of HDAC3 with
active caspase-3 in response to ET treatment. Whole-cell lysates were immunoprecipitated with anti-HDAC3 antibody, and subsequently immunoblotted
with the indicated antibodies. Arrow indicates cleaved HDAC3. (d) Knockdown of PDCD5 prevents cytoplasmic cleavage of HDAC3 in response to ET
treatment. Following cell fractionation, fractions were immunoblotted with the indicated antibodies. (e) Overexpression of PDCD5 enhances ET-induced
cytoplasmic translocation of HDAC3. Immunoﬂuorescence analysis was performed as described in the Supplementary Experimental Procedures Section.
Representative images of three independent experiments are shown. (f) PDCD5 knockdown diminishes the ET-induced dissociation of HDAC3 from p53.
Indicated shRNA-expressing HCT-116 cells were treated with ET. Whole-cell lysates were analysed by western blotting with the indicated antibodies.
(g) Overexpression of PDCD5 dissociates HDAC3 from p53. Cells were transfected with PDCD5 plasmids. Immunoprecipitation and immunoblotting
analyses were performed with the indicated antibodies. (h,i) PDCD5 increases p53 acetylation and stability via mediating HDAC3 cleavage. Cells were
treated with ET (h) or cycloheximide (i) and subsequently immunoblotted with the indicated antibodies. Scale bar, 10 mm.
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on the interaction between HDAC3 and p53 and the inhibition of
p53 acetylation and stability by HDAC3 overexpression
(Supplementary Fig. 8a). Given the negative role of MDM2 in
PDCD5-induced p53 acetylation and activation28, we next
examined the involvement of MDM2 in the PDCD5–HDAC3–
p53 pathway using p53/MDM2 double-knockout mouse
embryonic ﬁbroblasts (MEFs). PDCD5WT, but not mutant
PDCD5E16D, induced p53 acetylation and stabilization in p53/
MDM2 double-knockout MEFs (Supplementary Fig. 8b).
Overexpression of HDAC3WT, but not the inactive
HDAC3Y298F mutant, efﬁciently reduced p53 acetylation
independently of MDM2 (Supplementary Fig. 8c). Collectively,
these results suggest that the PDCD5–HDAC3 network regulates
p53 stabilization independently of MDM2 and MAGE-A2. Both
cycloheximide treatment and ET time-course experiments
veriﬁed that PDCD5 mediates HDAC3 degradation and p53
acetylation in response to genotoxic stress (Fig. 2h,i). Collectively,
these results suggest that PDCD5 stabilizes p53 by inhibiting
HDAC3–p53 interactions, which leads to translocation of
HDAC3 from the nucleus to the cytosol and subsequent
caspase-3-dependent cleavage.
PDCD5 induces cleavage and degradation of HDAC3. HDAC3
cleavage by PDCD5 correlates with increased p53 acetylation;
however, HDAC3 cleavage is not observed during ET treatment
at the time (4 h) when p53 is activated. We next examined
whether the cleaved form of HDAC3 was rapidly degraded during
ET treatment. At 2 h after the start of ET treatment, p53
acetylation at multiple lysine residues increased when the
cleavage of HDAC3 was observed in the presence of MG132
(Supplementary Fig. 9a). At 4 h after the start of ET treatment,
B20% of HDAC3 was observed as the cleaved form in the
presence of MG132. At 12 h after the start of ET treatment, we
found that B60% of full-length HDAC3 in the cell lysate
was cleaved and dissociated from p53, which is consistent with
maximum p53 activation (Fig. 3a). However, PDCD5 knockdown
strongly reduced the percentage of HDAC3 cleavage and the
dissociation of HDAC3 from p53 in response to ET treatment
(Fig. 3b; Supplementary Fig. 9a). Similar results were observed by
PDCD5 overexpression in the presence of MG132
(Supplementary Fig. 9b). We found that ET treatment induced
the time-dependent ubiquitination and cleavage of HDAC3
(Fig. 3c); however, depletion of PDCD5 substantially reduced
HDAC3 ubiquitination (Fig. 3d). By contrast, uncleaved mutant
HDAC3D391A was not ubiquitinated in response to ET treatment
(Fig. 3e). Confocal microscopy analysis showed the nuclear
retention of uncleaved HDAC3D391A even after ET treatment,
suggesting that cytoplasmic translocation and cleavage of HDAC3
is required for HDAC3 ubiquitination (Supplementary Fig. 9c).
Moreover, HDAC3D391A overexpression conferred stronger
inhibition of PDCD5-induced p53 acetylation and activation
that was conferred by HDAC3WT (Fig. 3f). These results indicate
that PDCD5 induces caspase-3-dependent HDAC3 cleavage,
which leads to ubiquitin-dependent proteasomal degradation of
HDAC3.
CK2a-mediated phosphorylation enhances PDCD5 stabilization.
We next examined how PDCD5 levels are increased and how
PDCD5 is translocated into the nucleus in response to ET
treatment. CK2a phosphorylated PDCD5 at Ser-119; mutation of
this site disrupted the pro-apoptotic function of PDCD5 (ref. 29).
Therefore, we tested whether CK2-mediated phosphorylation
increased PDCD5 stability. Treatment with MG132 signiﬁcantly
increased PDCD5 levels, whereas CK2a knockdown diminished
the effect of MG132 on PDCD5 stabilization (Fig. 4a). A
cycloheximide time-course experiment showed that CK2a
enhanced PDCD5 stability. CK2a knockdown reduced
PDCD5 stability, indicating a crucial role for CK2a in PDCD5
stabilization (Supplementary Fig. 10a). To conﬁrm these results,
we generated a PDCD5 antibody that speciﬁcally recognized the
phosphorylated Ser-119 residue. The phospho-speciﬁc antibody
detected phosphorylated Ser-119 in PDCD5WT, but not in the
PDCD5S119A mutant, verifying its speciﬁcity (Supplementary
Fig. 10b). We observed that the levels of both PDCD5 and
phosphorylated PDCD5 concurrently increase in response to ET
treatment. However, CK2 knockdown diminished the levels
of PDCD5 and phosphorylated PDCD5, and reduced HDAC3
cleavage and p53 activation in response to ET (Fig. 4b;
Supplementary Fig. 10c). CK2 overexpression markedly reduced
PDCD5 ubiquitination (Fig. 4c) and increased PDCD5 stability, but
not PDCD5 mRNA levels (Supplementary Fig. 10d). These results
indicate that CK2-mediated phosphorylation of Ser-119 is required
for PDCD5 stabilization.
IPO13 mediates nuclear translocation of phosphor-PDCD5.
We examined how PDCD5 is translocated into the nucleus in
response to ET treatment. First, we performed bioinformatics
analysis to search for nuclear localization signals (NLSs) in
PDCD5, and identiﬁed a candidate NLS sequence in the
N-terminal (1 20 a.a.) region. Then, we used site-directed
mutagenesis to generate several different PDCD5 point mutants.
Each PDCD5 point mutant was transfected into HCT-116 cells,
and nuclear translocation was examined by confocal microscopy.
Mutation of the candidate NLS sequence had no effect on PDCD5
subcellular localization in response to ET treatment
(Supplementary Fig. 11a). However, mutation of the Ser-119
residue blocked PDCD5 translocation into the nucleus that was
observed with wild-type PDCD5. Strikingly, the phospho-
Figure 3 | PDCD5 mediates ubiquitin-dependent proteasomal degradation of HDAC3 via C-terminal cleavage of HDAC3. (a) MG132 treatment induces
accumulation of cleaved HDAC3. Cells were treated with ET (50mM) and/or MG132 (10 mM, 3 h). Whole-cell lysates were immunoblotted with the
indicated antibodies. Arrow indicates cleaved HDAC3 (left panel). Intensities of protein bands obtained from the immunoblotting assay were quantiﬁed
with ImageJ (right panel) and normalized with respect to that of b-actin. Relative % intensity was calculated by dividing the normalized intensity by the sum
of intensities from both cleaved and full-length HDAC3. Error bars, s.d. (n¼ 3). (*Po0.01 versus without ET.) (b) PDCD5 knockdown diminishes the
reduction and cleavage of full-length HDAC3. shcontrol or stable shPDCD5-expressing HCT-116 cells were treated with ET and/or MG132. Whole-cell
lysates were immunoprecipitated and immunoblotted with the indicated antibodies (left panel). Relative % intensity was calculated as described above
(right panel). Error bars, s.d. (n¼ 3). (*Po0.01 versus without ET.) (c) HDAC3 ubiquitination increases in a time-dependent manner in response to ET
treatment. Cells were transfected with HA-Ub plasmid and treated with MG1432 and/or ET. Whole-cell lysates were immunoprecipitated with anti-HDAC3
(C) antibody and immunoblotted with the indicated antibodies. (d) PDCD5 knockdown diminishes HDAC3 ubiquitination in response to ET. Whole-cell
lysates were immunoprecipitated with anti-HDAC3 (C) antibody and immunoblotted with the indicated antibodies. (e) Mutation of Asp-391 abolishes
ET-induced HDAC3 ubiquitination. Cells were transfected with HA-Ub and the indicated Flag-tagged plasmids, and treated with ET and/or MG132.
Whole-cell lysates were immunoprecipitated with anti-Flag antibody and immunoblotted with the indicated antibodies. (f) Mutation of Asp-391 potentiates
the action of HDAC3 in the inhibition of PDCD5-mediated p53 acetylation. Cells were transfected with the indicated Flag-tagged plasmids. Whole-cell
lysates were immunoblotted with the indicated antibodies.
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mimetic PDCD5 mutant (PDCD5S119D) localized primarily in the
nucleus even without ET treatment, suggesting that CK2-medi-
ated phosphorylation of Ser-119 is required for nuclear translo-
cation of PDCD5 in response to genotoxic stress (Fig. 4d). Cell
fractionation analysis again veriﬁed the above ﬁnding that
phosphor-PDCD5 rapidly moved into nucleus upon ET treat-
ment. However, knockdown of CK2a blocked the nuclear
localization of PDCD5 (Supplementary Fig. 11b,c). There are
evidences that phosphorylation activates non-canonical transport
signals and the phosphorylated motif is recognized by nuclear
receptor importin-b family without intervention of an importin
a-like protein30. Strikingly, we found that PDCD5 selectively
binds to a nuclear transport protein IPO13 in response to ET, and
the knockdown of IPO13 abrogated the nuclear translocation of
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endogenous PDCD5 (Fig. 4e,f; Supplementary Fig. 11d).
Importantly, knockdown of IPO13 abolished the nuclear
retention of phospho-mimetic PDCD5S119D mutant (Fig. 4g).
Moreover, IPO13 strongly binds to phosphor-mimetic
PDCD5S119D but not with the phospho-mutant PDCD5S119A,
indicating that IPO13 is indispensable for nuclear translocation of
phosphor-PDCD5 (Supplementary Fig. 11f). Finally,
overexpression of PDCD5S119D induced HDAC3 cleavage and
p53 activation more strongly than that induced by wild-type
PDCD5. By contrast, the phospho-mutant PDCD5S119A had no
effect on HDAC3 cleavage and p53 activation (Fig. 4h).
Collectively, these results demonstrate that CK2-dependent
phosphorylation is required for IPO13-mediated nuclear
translocation of PDCD5, which leads to HDAC3 cleavage in
response to ET treatment.
PDCD5 promotes p53 function via HDAC3 inhibition. To
investigate the functional signiﬁcance of PDCD5-mediated
HDAC3 cleavage on p53-dependent apoptosis, we observed the
modulation of pro-apoptotic genes after knocking down or
overexpressing PDCD5 and/or HDAC3. PDCD5 knockdown
abrogated both ET- and staurosporine (STS)-induced transcrip-
tion of p53-target genes, Puma and Bax. Accordingly, over-
expression of PDCD5 further enhanced ET-induced
p53-target gene expression. Strikingly, coexpression of both
PDCD5 and HDAC3 attenuated the positive action of PDCD5
on ET-induced p53-target gene expression, indicating an
antagonistic function of HDAC3 in PDCD5-mediated apoptosis
(Fig. 5a).
Next, we examined whether the pro-apoptotic function of
PDCD5 is dependent on p53. Overexpression of PDCD5 in HCT-
116 (p53þ /þ ) cells yielded a signiﬁcant increase in annexin
V-positive cells compared with HCT-116 (p53 / ). Moreover,
both inhibition and knockdown of caspase-3 fully abrogated
PDCD5-enhanced apoptotic cell death in HCT-116 (p53þ /þ )
cells, but not in HCT-116 (p53 / ), suggesting that PDCD5
promotes genotoxic stress-induced apoptosis in a p53-dependent
manner (Fig. 5b; Supplementary Fig. 12a). Strikingly, over-
expression of HDAC3 selectively antagonized PDCD5-mediated
apoptosis, indicating the exclusive role of HDAC3 in PDCD5-
mediated apoptotic signalling (Fig. 5c; Supplementary Fig. 12b).
Although depletion of class I HDACs commonly enhanced
ET-induced apoptosis, likely due to their activity in genome
maintenance, depletion of HDAC3 further enhanced ET-induced
apoptosis of HCT-116 (p53þ /þ ) cells than that induced by other
HDACs (Fig. 5d). Collectively, these data indicate that PDCD5
negatively regulates anti-apoptotic action of HDAC3 in a
p53-dependent manner.
p53 mediates transcriptional activation upon binding to the
promoter region of its target genes. Intriguingly, structure
analysis of PDCD5 protein using Conserved Domain Database
showed that PDCD5 possesses a double-strand DNA-binding
domain31. Given our ﬁndings that show enhanced interaction
between PDCD5 and p53 in response to ET, we next explored the
possibility that PDCD5 forms a complex with p53 that enhances
recruitment to the promoter region of target genes. For this, we
performed chromatin immunoprecipitation (ChIP) analyses
against the p53-binding site (p53-RE) on Bax. ChIP assays
showed that ET efﬁciently induced the binding of p53 and p300
to p53-RE of Bax (Fig. 5e, ﬁrst panel). ChIP and re-ChIP analyses
further veriﬁed the presence of an acetylated p53–PDCD5–p300
complex in the p53-RE region of Bax (Fig. 5e, second panel).
Strikingly, the depletion of PDCD5 abrogated ET-induced
recruitment of the p53–p300 complex to the p53-binding site of
Bax (Fig. 5e, ﬁrst panel). In addition, the restoration of p53 in
HCT-116 (p53 / ) cells efﬁciently regained the effect of ET on
recruitment of PDCD5 and p300 to Bax. Knockdown of PDCD5,
however, greatly abolished binding of the p53–p300 complex to
Bax (Fig. 5e, fourth panel). Similar results were observed in the
p53-RE on the Puma gene (Supplementary Fig. 13a). Collectively,
these data demonstrate that PDCD5 mediates the removal of
HDAC3 from p53 upon genotoxic stress, and subsequently forms
a complex with p53 and p300 that promotes transcriptional
activation of p53-target genes.
PDCD5 mediates acetylation-dependent p53 stabilization. Our
results illustrating the p53-dependent action of PDCD5 in gen-
otoxic stress responses led us to further investigate whether
PDCD5 is critical for the stabilization and activation of p53. For
this, we generated PDCD5ﬂox/ﬂox mice (Supplementary Fig. 14).
MEFs generated from these mice were subjected to a Cre
recombinase (Ad-Cre)-expressing adenovirus to delete PDCD5,
generating a PDCD5 / MEF line. Ad-Cre recombinase treat-
ment depleted most PDCD5 protein in MEFs derived from
PDCD5f/f mice (Fig. 6a). Depletion of PDCD5 strongly reduced
HDAC3 cleavage and p53 activation in response to ET treatment
and p53 overexpression (Fig. 6a; Supplementary Fig. 15a). Con-
sistently, a Mdm2 inhibitor, nutlin3a treatments had negligible
effects on HDAC3 cleavage and p53 activation in PDCD5 /
MEFs (Supplementary Fig. 15b). However, rescue of PDCD5 /
MEFs with haemagglutinin (HA)-tagged PDCD5WT, but not with
PDCD5E16D, markedly increased p53 activity, HDAC3 cleavage
and recruitment of the p53–p300 complex to the p53-RE of Bax
and Puma, indicating that PDCD5 is required for p53 activation
via HDAC3 cleavage (Fig. 6b,c; Supplementary Figs 13b and
15b,c). Importantly, rescue of PDCD5-knockdown p53 /
Figure 4 | Casein kinase 2a enhances the stability and IPO13-mediated nuclear translocation of PDCD5 during genotoxic stress responses.
(a) CK2a knockdown diminishes the effect of MG132 on PDCD5 stability. HCT-116 (p53þ /þ ) cells were transfected with MG132 or shCK2a and
immunoblotted with the indicated antibodies. (b) CK2a knockdown abolishes ET-induced HDAC3 cleavage, PDCD5 induction and PDCD5 phosphorylation.
Either shcontrol or stable shCK2a-expressing HCT-116 cells were treated with ET. Whole-cell lysates were immunoblotted with the indicated antibodies.
(c) CK2a overexpression inhibits PDCD5 ubiquitination. Cells were transfected with HA-Ub and the indicated Flag-tagged plasmids, and treated with
MG132. Whole-cell lysates were immunoprecipitated with anti-Flag antibody and immunoblotted with the indicated antibodies. (d) CK2-mediated
phosphorylation is required for ET-induced PDCD5 nuclear translocation. Cells were transfected with the indicated Flag-PDCD5 plasmids and treated with
ET. Immunoﬂuorescence analysis was performed as described in the Supplementary Experimental Procedures Section. (e) IPO13 selectively interacts with
PDCD5 upon genotoxic stress response. Cells were transfected with HA-PDCD5 and the indicated Flag-tagged plasmids, and treated with ET. Whole-cell
lysates were immunoprecipitated and immunoblotted with the indicated antibodies. (f) Knockdown of IPO13 abrogated the nuclear translocation of
endogenous PDCD5 in response to ET. HCT-116 cells were transfected with the indicated siRNAs and treated with ET. Immunoﬂuorescence analysis was
performed as described in the Supplementary Experimental Procedures Section. (g) IPO13 knockdown abolishes the nuclear translocation of phosphor-
PDCD5. HCT-116 cells were transfected with the indicated siRNAs and Flag-PDCD5 plasmid, and treated with ET. Immunoﬂuorescence analysis was
performed as described in the Supplementary Experimental Procedures Section. (h) Phospho-mimetic PDCD5S119D mutant further promotes p53
acetylation and stabilization. Cells were transfected with the indicated Flag-PDCD5 plasmids. Whole-cell lysates were immunoblotted with the indicated
antibodies. Scale bar, 10mm.
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MEFs with p53 and wild-type PDCD5WT, but not mutant
PDCD5E16D, resulted in regained p53 action on ET-induced
HDAC3 cleavage, target gene expression and apoptosis (Fig. 6d;
Supplementary Fig. 15d). These results again verify that PDCD5
and p53 are mutually required for genotoxic stress-induced
apoptosis and HDAC3 cleavage. We observed that HDAC3
knockdown rescued p53 suppression caused by PDCD5
depletion (Fig. 6e; lane 3 versus 4). Restoration of PDCD5WT, but
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not PDCD5E16D, further enhanced the effect of HDAC3 knock-
down on p53 acetylation and activation (lane 2 versus 5),
again conﬁrming the crucial role of PDCD5 in acetylation-
induced p53 stabilization (Fig. 6e; Supplementary Fig. 15e).
Notably, overexpression of uncleaved mutant HDAC3D391A
markedly suppressed ET-induced p53 acetylation and activation,
as well as apoptosis, when compared with wild-type HDAC3WT.
As expected, the cleaved form of HDAC3 (HDAC31–391) had
negligible effects on both p53 activation and apoptosis, support-
ing our notion that HDAC3 function is negatively regulated
during genotoxic stress responses (Fig. 6f; Supplementary
Figs 13c and 15f).
To further corroborate the critical role of PDCD5 in genotoxic
stress-induced DNA damage in vivo, PDCD5f/f mice were treated
with ET followed by injection of adenovirus for green ﬂuorescent
protein (GFP) or Cre recombinase to ablate PDCD5 mRNA
expression in liver. ET injection signiﬁcantly induced the HDAC3
cleavage and levels of p53 at 1 and 2 days when compared
without ET injection. However, depletion of PDCD5 markedly
diminished HDAC3 cleavage and levels of p53. As expected, the
mRNA levels of Puma and p21 were not increased in the
depletion of PDCD5 (Fig. 6g). Collectively, these data demon-
strate that PDCD5 plays an essential role in p53 activation by
modulating the decay of HDAC3 in vivo.
Reduction of PDCD5 and p53 enhances gastric tumorigenesis.
Reduced expression of PDCD5 has been reported in patients with
multiple cancer types including gastric, lung, ovarian and
glioma16–18,32. We investigated the pathological correlation
between PDCD5 and p53 in Korean gastric cancer samples.
Tumour tissues from 78 lymph-node-negative (N0-stage patients
having no lymph node metastasis) gastric adenocarcinoma
patients were used to generate gene expression proﬁles using
Illumina human bead arrays (HumanHT-12, v3.0, Illumina, San
Diego, CA). Pearson correlation coefﬁcient calculations between
PDCD5 and p53 in gastric cancer patients’ gene expression
proﬁles revealed a strong positive correlation (r¼ 0.42;
P¼ 0.00014) (Fig. 7a, upper panel). When we investigated the
prognostic power of PDCD5 and p53, neither PDCD5 nor p53
expression levels alone showed signiﬁcant prognostic
discrimination among gastric cancer. However, the combined
signature of PDCD5 and p53 showed strong prognostic powers in
N0-stage gastric cancer patients (log-rank test P¼ 0.015) (Fig. 7a,
lower left panel). As all of stage 1 and 2a patients survived, we
next sub-stratiﬁed patients into three groups: stage 1 and 2a
patients, stage 2b PDCD5 plus p53 (high) and stage 2b PDCD5
plus p53 (low). Patients showing increased expression of PDCD5
and p53 showed relatively good prognostic outcomes (over 80%
5-year survival rate), while the prognostic outcome of patients
showing low expression of PDCD5 and p53 in stage 2b was more
than 50% of death rates. We conclude that non-lymph node
metastasis gastric cancer patients can be stratiﬁed based on
disease stage and PDCD5 and p53 signature to show distinct
prognostic differences (log-rank test P¼ 0.000132) (Fig. 7a, lower
middle/right panel).
We again veriﬁed PDCD5-dependent p53 action in response to
genotoxic stress using the wild-type p53-positive gastric cancer
cell, AGS. As consistently, ET treatment had negligible effects on
HDAC3 cleavage and p53 activation in the absence of PDCD5.
Moreover, knockdown of HDAC3 markedly increased p53
stability and activation, while depletion of PDCD5 abrogated
this effect (Fig. 7b). Notably, knockdown of HDAC3 further
potentiated the effects of PDCD5 restoration on ET-induced p53
activation and HDAC3 cleavage, supporting our notion that
PDCD5 promotes p53 acetylation by suppressing HDAC3
function (Fig. 7c). Importantly, reduction of both PDCD5 and
p53 levels diminished the effect of ET on DNA damage response
more than knockdown of either protein individually (Fig. 7d).
Finally, an in vivo tumorigenicity assay using subcutaneous
injection of AGS cells into nude mice demonstrated that
reduction of either PDCD5 or p53 signiﬁcantly increased the
tumour growth compared with control short hairpin RNA
(shRNA) (Supplementary Fig. 16a–c). Strikingly, reduction of
both PDCD5 and p53 further enhanced tumour growth
and chemoresistance of AGS cells as compared with reduction
of the respective protein (Fig. 7e; Supplementary Fig. 16d).
Co-knockdown of PDCD5 and HDAC3 signiﬁcantly increased
the chemosensitivity of AGS cells compared with knockdown
of PDCD5 alone, indicating a negative action of HDAC3 in
p53-mediated genotoxic stress responses (Fig. 7f; Supplementary
Fig. 16e,f). Collectively, these data demonstrate that reduced
levels of PDCD5 and p53 enhance in vivo tumorigenic growth of
AGS gastric cancer cells and correlate with poor survival in
gastric cancer patients.
Discussion
Here, we found that p53 function is reversibly regulated by both
HDAC3 and PDCD5 during genotoxic stress response. There has
been accumulating evidence that inhibition of HDAC3 enhances
p53 acetylation and stability in human cancer and normal cell
lines7,8,33. Furthermore, a recent report showed that HDAC3
suppresses p53 activity in coordination with MAGE-A, which
confers resistance to chemotherapeutic agents9. However, we here
observed direct interaction between HDAC3 and p53, and found
that HDAC3 deacetylated p53 in vitro. These data suggest that
HDAC3 inhibition directly affects p53 acetylation. Furthermore,
MAGE-A knockdown had no effect on HDAC3–p53 interaction
or HDAC3-mediated inhibition of p53 acetylation and stability.
On the basis of these results, it is likely that HDAC3 regulates the
acetylation of p53 independently of MAGE-A. We do not exclude
the possibility that MAGE-A recruits HDAC3 to inhibit p53
function under certain cellular stresses or a certain type of cells.
Further work is necessary to elucidate functional relationships
between HDAC3 and MAGE-A in regulating p53 activity.
Although there is evidence for HDAC3 cleavage during
apoptosis, a detailed understanding of the effects of C-terminal
Figure 5 | PDCD5 promotes p53-dependent apoptosis via selective inhibition of HDAC3. (a) Overexpression of HDAC3 suppresses the
PDCD5-mediated transcription of p53-target genes. Cells were transfected with indicated siRNAs and/or plasmids and treated with either ET or STS. The
levels of indicated genes were analysed by real-time PCR. Error bars, s.d. (n¼ 3). *Po0.05. (b) PDCD5 promotes p53-dependent apoptosis in a caspase-
3-dependent manner. Cells were transfected with indicated plasmids and treated with ETand/or Z-DQMD. Annexin V-positive cells were assessed by ﬂow
cytometry. A representative ﬁgure of three independent experiments is shown. (c) HDAC3, but not other class I HDACs tested, selectively antagonizes
PDCD5-enhanced apoptosis. Annexin V-positive cells were assessed by ﬂow cytometry. Error bars, s.d. (n¼ 3). *Po0.05. (d) Knockdown of HDAC3
signiﬁcantly enhances ET-induced apoptosis. Annexin V-positive cells were assessed by ﬂow cytometry. Error bars, s.d. (n¼ 3). *Po0.05; **Po0.01.
(e) PDCD5 is required for ET-induced recruitment of the p53–p300 complex to the promoter region of Bax. Cells were transfected with indicated plasmids
and/or shPDCD5, and then treated with ET. ChIP and re-ChIP assays were performed with the indicated antibodies. Precipitated samples were analysed by
real-time PCR, and results are presented as the percentage of input. Error bars, s.d. (n¼ 3). *Po0.05, **Po0.01 versus without ET; #Po0.05 versus
without ET; ##Po0.05 versus ETþHA-p53WT.
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cleavage on HDAC3 function is lacking. In this study, we found
that PDCD5-mediated HDAC3 cleavage leads to ubiquitin-
dependent proteasomal degradation of HDAC3. PDCD5 knock-
down strongly reduced HDAC3 ubiquitination in response to ET
treatment. Overexpression of uncleaved HDAC3D391A inhibited
PDCD5-induced p53 acetylation and stabilization more effec-
tively compared with that of wild-type and cleaved (1 391)
HDAC3. We showed that PDCD5 competitively inhibited
HDAC3–p53 interaction in response to ET treatment, whereas
overexpression of the PDCD5E16D mutant, which is defective in
its interaction with p53, failed to induce HDAC3 cleavage and
p53 activation. These results indicate that PDCD5 and HDAC3
competitively bind to p53 in response to ET treatment, which
induces HDAC3 cleavage by caspase-3 and ultimately leads to
degradation of the cleaved form of HDAC3.
Previous reports show that PDCD5 is rapidly upregulated and
translocated into the nucleus during DNA damage responses;
however, the underlying mechanism was unknown. We found that
CK2 participated in the positive regulation of PDCD5 function
during genotoxic stress responses. We generated phospho-speciﬁc
PDCD5 antibody, which conﬁrmed that CK2-mediated phosphor-
ylation of PDCD5 at Ser-119 increased concurrently with
increasing PDCD5 levels during ET treatment. We showed that
CK2 depletion blocked ET-induced PDCD5 stabilization and
phosphorylation, and CK2-mediated PDCD5 phosphorylation was
required for nuclear translocation of PDCD5. The phospho-
mimetic PDCD5 mutant was localized primarily in the nucleus
regardless of ET treatment, and its overexpression more efﬁciently
induced HDAC3 cleavage and p53 acetylation more effectively
than that of wild-type PDCD5, indicating a positive action of CK2
in the pro-apoptotic function of PDCD5. Accumulating evidence
demonstrates that CK2 enhances the stability or nuclear
translocation of target proteins via phosphorylation of Ser/Thr
residues34–36. Our results indicate that CK2 positively affects
PDCD5 function by enhancing both stability and nuclear
translocation. Although there is no obvious NLS in PDCD5, we
found that phosphorylated PDCD5 is recognized and imported
into the nucleus by importin IPO13, which is similar to ERK1/2
and ASF/SF2 (ref. 30). Importantly, knockdown of IPO13
abrogated the nuclear translocation of phospho-mimetic
PDCD5S119D mutant, highlighting that IPO13 mediates nuclear
translocation of phosphor-PDCD5. Further work is necessary to
unravel the details of PDCD5 nuclear transport.
On the contrary to previous ﬁndings11,12, we found that
inhibition of caspase-3, but not caspase-7, completely blocked
HDAC3 cleavage by ET and PDCD5 overexpression. These data
suggest that caspase-3 is the principal executioner for PDCD5-
mediated HDAC3 cleavage upon genotoxic stress. One possible
scenario is that since caspase-3 is a major effector in human
cancer cell lines, it is sufﬁcient for proteolysis of the majority of
substrates that are cleaved during the end of apoptosis.
Furthermore, it has been shown that both caspase-3 and
caspase-7 commonly cleave certain substrates such as PARP,
but exhibit differential activity towards multiple substrates such
as Bax, XIAP and cochaperone p23 (ref. 37). However, we do not
exclude the possibility that caspase-7 may be capable of
functionally substituting for caspase-3 in situations where both
proteases are expressed at similar levels such as Jurkat and
NIH3T3 cell lines.
Intriguingly, PDCD5 seems to possess a double-strand DNA-
binding domain. This raises the possibility that PDCD5 binds to
chromatin with p53 to activate transcription of pro-apoptotic
genes. In here, we found that p53 is recruited to p53-RE of Bax and
Puma after forming the p53–p300 complex in the presence of
PDCD5. Moreover, rescue of PDCD5 / MEFs with PDCD5WT,
but not mutant PDCD5E16D, markedly induced the formation of
the p53–p300 complex in the promoter region of Bax and Puma
genes. This ﬁnding suggests that PDCD5–p53 interaction is
required for p53 binding to the target gene promoters, and this
association promotes the transcription of pro-apoptotic genes
(Supplementary Fig. 16g). Finally, our clinical analyses conﬁrmed a
positive correlation between PDCD5 and p53 and gastric cancer
patient survival rates. Our data showed that survival rates of stage
2b gastric cancer patients with reduced levels of both PDCD5 and
p53 are markedly decreased compared with those patients with
reduction of PDCD5 alone. Furthermore, this result is well
consistent with that from the mice xenograft assay. This suggests
that reduction of PDCD5 and p53 levels may contribute to the
early progression of human gastric cancer.
The use of HDAC inhibitors as anticancer treatments has been
extensively studied, and several inhibitors are currently in clinical
trials. Development of HDACi-based anticancer drugs, however,
is limited due to unfavourable toxicities38. Though, recent studies
in the development of selective HDAC inhibitors have
demonstrated that HDAC3-selective inhibitors are promising
candidates for anticancer drugs39,40. Thus, future directions for
developing clinical applications for HDACi may focus on the use
of HDAC subtype-speciﬁc inhibitors. A better understanding of
individual HDAC function will pave the way for development of
prospective HDAC inhibitors as anticancer therapeutics.
Methods
Immunoprecipitation and antibodies. The antibody against mouse PDCD5 was
generated by LabFrontier (Anyang, South Korea) using the synthetic peptide
TEKKTTVKFNRRKVMDSDEDDADY and used at a 1:500 dilution. The antibody
against HDAC3 (N) and (C) were generated by LabFrontier using the synthetic
peptide CLNVPLRDGIDDQSYKHLFQ and YDGDHDNDKESDVEI, respectively,
and used at a 1:1,000 dilution. The antibody against phosphor-PDCD5Ser119 was
generated by LabFrontier using the synthetic peptide 111FNRRKVMDpSDED
DDY125 (1:1,000). Antibodies against HDAC1 (sc-78972), HDAC2 (sc-7899),
HDAC8 (sc-11405), pro-caspase-8 (sc-7272), pro-caspase-9 (sc-11405), p53
(sc-126 and sc-6243), caspase-3 (sc-7148), caspase-7 (SC-56063), p21 (sc-397),
HA (sc805), MAGE-a2 (sc-130164), HDAC3(C-terminal) (sc-11417) and
pro-caspase-12 (sc-70227) were purchased from Santa Cruz Biotechnology Inc.
Figure 6 | PDCD5 is required for genotoxic stress-induced HDAC3 cleavage and p53 activation. (a) Depletion of PDCD5 abrogated the ET-induced
HDAC3 cleavage and p53 activation. MEFs were infected with Ad-Cre or Ad-GFP and then electroporated with Myc-p53 or treated with ET (50 mM, 8 h).
Whole-cell lysates were immunoblotted with indicated antibodies. Arrow indicates cleaved HDAC3. (b) PDCD5 promotes ET-induced p53 activation and
HDAC3 cleavage. PDCD5 / MEFs were electroporated with indicated plasmids, treated with ET, lysed and then analysed by immunoblotting.
(c) Restoration of PDCD5 into PDCD5 / MEFs induces the recruitment of the p53–p300 complex to the promoter region of Bax. ChIP assays were
performed with the indicated antibodies. Error bars, s.d. (n¼ 3). *Po0.05, **Po0.01. (d) Both PDCD5 and p53 are mutually required for ET-induced
activation of apoptosis. Stable shPDCD5-expressing p53 / MEFs were electroporated with indicated plasmids and treated with ET. (e) Knockdown of
HDAC3 rescues the suppression of p53 caused by depletion of PDCD5. PDCD5 / MEFs were electroporated with indicated plasmids and/or shHDAC3,
and cell lysates were analysed by immunoblotting. (f) Negative effect of cleavage at Asp-391 on the anti-apoptotic function of HDAC3. Cell lysates were
analysed by immunoblotting. (g) Ablation of PDCD5 abolishes the genotoxic stress response in vivo. Mice were injected with ET (10mg kg 1) for the
indicated days. Adenovirus expressing GFP or Cre recombinase was injected in mice 6 days before ET injection, as indicated. Tissues from individual livers
were harvested and processed for western blotting. Total RNA was isolated from individual livers, and qRT–PCR was performed for the indicated genes.
Error bars, s.d. (n¼8). *Po0.05 versus without ET; #Po0.05 versus ET (2 days).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8390
12 NATURE COMMUNICATIONS | 6:7390 |DOI: 10.1038/ncomms8390 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
(Santa Cruz, CA, USA). Antibody against PDCD5 (12456-1-AP) was purchased
from Proteintech Group Inc. (Chicago, IL, USA). FLAG (F3165) and b-actin
(A5441) antibodies were obtained from Sigma-Aldrich. Myc (#2278S), acetyl-
p53K379 (#2570), acetyl-p53K382 (#2525S) and active-caspase-3 (#9661S) antibodies
were purchased from Cell Signaling (Beverly, MA, USA). Tubulin (05-829),
GAPDH (CB1001) and p300 (N446) antibodies were obtained from Millipore
(Billerica, MA, USA). PARP-1 (51-6639GR) antibody was purchased from BD
Transduction Laboratories (Lexington, KY, USA). Bax (1063-1) and acetyl-p53K373
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(#2204-1) antibodies were purchased from Epitomics Inc. PDCD4 (ab32831-100),
PDCD6 (ab133326), IPO13 (ab101374), acetyl-p53K381 (ab61241) and Puma
(ab133326) antibodies were purchased from Abcam (Cambridge, MA, USA). To
quantify the intensity of immunoblotting, images were analysed using the ImageJ
software (http://rsbweb.nih.gov/ij/). Brieﬂy, to analyse the individual images for
quantiﬁcation, RGB colour images obtained from the immunoblotting analysis
were converted to 8-bit grayscale images. Mean gray value and integrated density
were quantiﬁed on each object in images according to the guide instruction of
ImageJ. The results are shown as mean±s.d. calculated from three independent
experiments. Working dilutions or quantities of the antibodies used in the study
are summarized in Supplementary Table 3. Uncropped immunoblottings are
provided as Supplementary Fig. 17.
Yeast two-hybrid assay. HDAC3 bait plasmids (pGBKT7-HD3DO1 and
pGBKT7-HD3DO2) were transformed into the yeast strain AH109. Transformants
containing each bait plasmid were mated with the pre-transformed human Ovary,
Breast and Testis MATCHMAKER cDNA library (Clontech, Shiga, Japan). Two-
hybrid screening was performed according to the manufacturer’s protocol. Plas-
mids were harvested from the positive clones that grew in minimal media lacking
tryptophan, leucine, adenosine, histidine and b-galactosidase expression. Plasmids
were identiﬁed by DNA sequencing.
Mass spectrometry. The eluted immune complexes were precipitated with 20%
trichloroacetic acid and the pellets were washed four times with cold acetone. The
precipitated proteins were resuspended in 100mM ammonium bicarbonate (pH
8.0) with 10% acetonitrile and incubated with sequencing-grade trypsin (Promega,
Fitchburg, WI, USA) at a concentration of 12.5 ngml 1 at 37 C for 4 h. Trypsin
reactions were quenched by addition of 5% formic acid, and peptides were desalted
using the C18 Stage Tip method. For each liquid chromatography–MS/MS analysis,
4 ml of sample was loaded onto an EASY-Spray C18 column (Thermo Scientiﬁc,
Waltham, MA, USA) and eluted using a 90-min 8–26% acetonitrile gradient. Mass
spectra were acquired with an LTQ Orbitrap XL linear ion trap mass spectrometer
(Thermo Scientiﬁc) using a data-dependent Top-10 method. Each sample was shot
twice in succession, followed by a wash with 70% acetonitrile and 30% isopropanol.
MS/MS data were analysed using the Coon OMSSA Proteomics Software Suite41.
Z-score is representative of the identiﬁcation of candidate interacting proteins.
Total Spectral Count (TSC) is for each identiﬁed protein from each
immunoprecipitation–MS/MS experiment.
Cell culture, siRNA and plasmids. Human colon carcinoma HCT-116 (p53þ /þ ),
HCT-116 (p53 / ) (Dr B. Vogelstein, Johns Hopkins University) and human
gastric cancer cell AGS (American Type Culture Collection) were maintained in
DMEM (Welgene, Korea) with 10% fetal bovine serum (Hyclone) and 1% anti-
biotics (Invitrogen, Carlsbad, CA, USA) at 37 C and 5% CO2. Short interfering
RNAs (siRNAs) were designed to target PDCD5, p53, HDAC1, HDAC2, HDAC3,
HDAC8, MAGE-a2, caspase-3 and caspase-7 mRNA (Supplementary Table 4).
Non-targeting siRNA (siCONTROL, Genepharma, Shanghai, China) was used as a
control. Cells were transfected with 200 nM chemically synthesized siRNA (Gen-
epharma) using Lipofectamine 2000 (Invitrogen) in 60-mm dishes or 12-well
plates. Mammalian expression plasmids for FLAG-HDAC1, Flag-HDAC2, FLAG-
HDAC3, FLAG-HDAC8, FLAG-PDCD5, Myc-PDCD5, HA-p53, FLAG-PDCD5
deletion mutants, FLAG-PDCD4 and FLAG-PDCD6 were constructed with stan-
dard PCR and cloned into the pSG5 vector (Supplementary Table 4). The FLAG-
HDAC3D391A, FLAG-HDAC31–391, FLAG-HDAC3WT-HA, FLAG-HDAC3D391A-
HA, FLAG-PDCD5L6R, HA-PDCD5E16D, shPDCD5-resistant HA-PDCD5WT and
shPDCD5-resistant HA-PDCD5E16D expression plasmids were derived from
FLAG-HDAC3 and HA-PDCD5 or Myc-PDCD5 using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Bacterial expression
plasmids for GST-HDAC3, GST-HDAC3N and GST-HDAC3C were constructed
with PCR and subcloned into the pGEX4T-1 vector. Glutathione S-transferase
(GST)-fusion proteins were expressed in the Escherichia coli strain BL21 (DE3)
with 0.5mM isopropyl-b-D-thiogalactoside for 2 h, and then isolated using Glu-
tathione Sepharose 4B beads (Peptron, Korea) according to the manufacturer’s
instructions. All constructs were veriﬁed by DNA sequencing.
Generation of PDCD5ﬂox/ﬂox mice and MEFs. Conditional targeting strategy of
pdcd5 was carried out by the insertion of a loxP site between exon 2 and exon 3. An
additional site was inserted upstream of exon 4 (Supplementary Fig. 13). Primers
used for genotyping are given below: P1, 50-CTTGGGACAAACGCTAGTCG-30 ;
P2, 50-GGAAACTGGACCTCACCAAA-30 ; P3, 50-GTCGGCTCTATGGCTT
CTGA-30 ; P4, 50-GCAGGGGTAAAACAGCAGAG-30; P5, 50-CAGTAAA-
TACCCACGGAGTT-30 . All mouse experiments were carried out on the 129S7/
SvEvBrdC57BL/6 mixed background. Wild-type and PDCD5f/f MEFs were
prepared from mouse embryos of wild-type and PDCD5f/f homozygotes as follows:
after isolation and genotyping of individual embryos seperately at embryonic day
13.5, MEFs with the same genotype were pooled and maintained until use. Animal
studies were performed after obtaining approval according to the guidelines of the
Institutional Animal Care committee of CHA Research Institute. Embryo head and
internal organs were removed, and the torso was minced. Cells were grown for two
population doublings (considered as one passage) and then viably frozen. MEFs
were used for all subsequent experiments. MEFs were maintained in DMEM
containing 10% fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA) and
subcultured 1:3 upon reaching conﬂuence. For electroporation of MEFs, 5 mg of
plasmid was electroporated into a suspension of 2 105 cells using a Neon
transfection system (Life Technologies, Grand Island, NY, USA).
Xenograft experiments. A suspension of 2 106 AGS cells in 100ml PBS was
injected subcutaneously into the right ﬂank of 5-week-old athymic BALB/c nu/nu
mice (Orient, Seoul, Korea). Each experimental group included eight mice. Tumour
size was monitored closely and measured every 6 days using a caliper. Three weeks
after injection, mice with comparable-sized tumours (100B200mm3) were selected
for treatment with ET (10mg kg 1), with 2-day intervals for 8 weeks. For siHDAC3
treatment, HDAC3 siRNA/in vivo jetPEI complexes were prepared in a volume of
20ml per tumour using the in vivo jetPEI (Polyplus Transfection, Illkirch, France)
delivery reagent (20mg siRNA/20ml jetPEI) according to the manufacturer’s
instructions. The xenografts reaching a tumour volume of 60–80mm3 were injected
intratumorally into each animal seven times with 2-day intervals. After 8 weeks of
ET treatment, mice were killed and tumours were harvested, photographed and
weighed. The volume of tumours was estimated using the formula: volume¼½
a b2, where a and b represent the largest and smallest diameters, respectively.
Animal studies were performed after obtaining approval according to the guidelines
of the Institutional Animal Care committee of the Ulsan College of Medicine.
Animal experiments. Eight mice per group were used for each experiment. Mice
were injected with adenovirus for GFP or Cre recombinase via tail vein injection. A
dosage of 1 109 plaque-forming units per mouse was used for adenovirus
delivery. Mice were injected with ET (10mg kg 1) from the 6th day post adeno-
virus injection for the indicated days. For the restoration experiment using PDCD5
adenovirus, a dosage of 1 109 plaque-forming units per mouse was injected from
the 2nd day post Cre adenovirus injection. Mice were anesthetized using ketamine
(80mg kg 1) and xylaxine (10mg kg 1) by intraperitoneal injection. Total pro-
tein and RNA were isolated from individual livers, and western blot analysis and
quantitative reverse transcription (qRT)–PCR were performed as described above.
Animal studies were performed after obtaining approval according to the guide-
lines of the Institutional Animal Care committee of CHA Research Institute.
Figure 7 | Reduction of both PDCD5 and p53 synergistically enhance in vivo tumorigenicity of gastric cancer cells. (a) Reduction of PDCD5 and p53
signiﬁcantly correlates with poor survival in stage 2b gastric cancer patients. Kaplan–Meier plots and log-rank test were used to estimate the prognostic
differences of categorized patient groups. (b) Depletion of PDCD5 diminishes the effect of HDAC3 knockdown on p53 acetylation and activation. AGS cells
were transfected with siHDAC3 and/or shPDCD5 as indicated, and treated with or without ET (75 mM, 8 h). Whole-cell lysates were immunoblotted with
indicated antibodies. (c) Restoration of PDCD5 with HDAC3 knockdown potentiates ET-induced p53 activation. Stable shPDCD5-expressing AGS cells
were transfected with indicated plasmids and/or siHDAC3, and then treated with ET. DNA damage of cells was determined by the TUNEL assay. Error bars,
s.d. (n¼ 3). *Po0.01. (d) Reduction of PDCD5 and p53 synergistically reduces the genotoxic response of AGS cells. Stable shPDCD5-expressing AGS cells
were transfected with indicated plasmids and/or siRNA, and then the cells were treated with ET. DNA damage of cells was determined by the TUNEL assay.
Error bars, s.d. (n¼ 3). *Po0.01. (e) Reduction of PDCD5 and p53 signiﬁcantly reduces the chemosensitivity of AGS cells. Stable AGS cells were injected
subcutaneously into the right ﬂank of nude mice. Four weeks after injection, mice with comparable-sized tumours (100B200mm3) were selected for
treatment with ET (10mg kg 1), with 2-day intervals for 8 weeks. Tumour volumes were measured for 12 weeks. Error bars indicate s.d. (n¼ 6). *Po0.05
versus without ETþshPuro. (f) Knockdown of HDAC3 reversed the impaired chemosensitivity of AGS cells by depletion of PDCD5. Stable shCon or
shPDCD5 AGS cells were injected subcutaneously into the right ﬂank of nude mice. Four weeks after injection, mice with comparable-sized tumours
(100B200mm3) were selected for treatment with etoposide (10mg kg 1), with 2-day intervals for 8 weeks. Detailed procedure for siHDAC3 treatment is
described in the Methods. Tumour volumes were measured for 12 weeks. *Po0.05 versus shCon without ET; **Po0.05 versus shCon with ET; #Po0.05
versus shPDCD5 with ET. Error bars indicate s.d. (n¼6).
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Gene expression data. Experiments and analysis for 78 samples from the YUSH
data set were conducted in the Yonsei University Severance Hospital. All specimens
from patients were collected and archived under the standard protocols with
codiﬁed patient identiﬁcation information. The need for informed consent for the
gene expression analysis was waived by the institutional review board of Severance
Hospital Yonsei University Health System, as the current study was considered a
retrospective review of anonymized clinical data. The information on clinic-
pathological characteristics of cancer patients was described in Supplementary
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Table 5. Gene expression proﬁles were generated by hybridizing labelled cRNAs to
Illumina human bead arrays (HumanHT-12, v3.0) containing 48,803 gene features.
Total RNA was extracted from the fresh frozen tissues using a mirVana RNA
isolation labeling kit (Ambion, Inc. Grand Island, NY, USA). Total RNA (500 ng)
was used for labelling and hybridization, according to the manufacturer’s protocol.
After the bead chips were scanned with an Illumina BeadArray Scanner, the
microarray data were normalized with a quantile normalization method in the
Linear Models for Microarray Data (LIMMA) package in the R language envir-
onment42. Kaplan–Meier plots and log-rank tests were used to estimate the
prognostic differences of categorized patient groups.
Duolink in situ proximity ligation assay (PLA). Duolink in situ PLA analysis was
performed according to the manufacturer’s instructions (OLink Biosciences,
Uppsala, Sweden). In short, paraformaldehyde-ﬁxed cells were washed with PBS,
incubated for 15min in 1.5% hydrogen peroxide, washed and blocked with
blocking solution. Primary rabbit antibody was applied, and the cells were incu-
bated with PLUS and MINUS secondary PLA probes against rabbit IgG only or
against both rabbit and mouse IgG. After the sample was incubated, hybridization,
ligation and ampliﬁcation steps were performed. Samples were mounted with
Duolink mounting medium, and then examined using a Zeiss LSM700 confocal
microscope (Carl Zeiss, Oberkochen, Germany).
HDAC activity assay. Brieﬂy, in the standard assay, 5 mg histone H4 tail peptides
were incubated with 0.25 mCi of [3H] acetyl coenzyme A (Amersham) in 20 ml
reaction buffer containing 50mM Tris (pH 8.0), 5% glycerol, 0.1mM EDTA,
50mM KCl, 1mM dithiothreitol (DTT), 1mM phenylmethylsulphonyl ﬂuoride
and 10mM sodium butyrate at 30 C for 2 h. Immunoprecipitated HDAC3 samples
were incubated with 3H-acetate-labelled H4 histone in 150ml of reaction buffer
(20mM Tris at pH 8.0, 150mM NaCl and 10% glycerol) overnight at room
temperature. Reactions were quenched with 1M HCl and 0.16M acetic acid (50 ml
in each sample). Released 3H-acetic acid was extracted with 600 ml ethyl acetate by
vortexing and centrifugation (1min at 9,300g). Ethyl acetate supernatants (300 ml
from each sample) were quantiﬁed by scintillation counting. The results are shown
as mean±s.d. calculated from three independent experiments.
RNA isolation and quantitative RT–PCR. PCR primers for qRT–PCR are
described in Supplementary Table 4. The concentration of complementary DNA
was normalized using GAPDH. QPCR analysis and quantiﬁcation was performed
using SYBR Green PCR master mix reagents and an ABI Prism 7700 sequence
detection system (Applied Biosystems, Carlsbad, CA, USA). All reactions were
performed in triplicate. Relative expression levels and s.d. were calculated using the
comparative method. The results are shown as mean±s.d. calculated from three
independent experiments.
Chromatin immunoprecipitation (ChIP) assay. Brieﬂy, B2 108 cells in 100-
mm dishes were ﬁrst treated with PBS containing 1% formaldehyde for 10min,
washed twice with cold PBS and then incubated with 100mM Tris (pH 9.4) and
10mM DTT at 30 C for 15min. The cells were then rinsed twice in PBS and
resuspended in 600 ml of SolA (10mM Hepes (pH 7.9), 0.5% NP-40, 1.5mM
MgCl2, 10mM KCl and 0.5mM DTT) by pipetting. After a short spin, the pellets
were resuspended in SolB (20mM Hepes (pH 7.9), 25% glycerol, 0.5% NP-40,
0.42M NaCl, 1.5mM MgCl2 and 0.2mM EDTA) containing protease inhibitors
followed by vigorous pipetting to extract nuclear proteins. After centrifugation at
13,000 r.p.m. for 30min, the nuclear pellets were resuspended in immunopreci-
pitation buffer (1% Triton X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.0), 150mM
NaCl and protease inhibitors) and sonicated to break chromatin into fragments of
0.5–1 kb average length. The ChIP assays were then preformed with the indicated
antibodies essentially as described, but without SDS in all buffers. Primers were
used for ChIP assays are described in Supplementary Table 4. All reactions were
normalized relative to input activities and are presented as mean±s.d. of three
independent experiments. The results are shown as percentage of input.
TUNEL assay. For the detection of apoptosis in cells, DNA fragmentation was
evaluated by the TdT-mediated dUTP nick end labelling (TUNEL) assay using an
HT Titer TACS Assay Kit (Cat No. 4822-96-K, Trivigen, Gaithersburg, MD, USA)
according to the manufacturer’s instructions. Brieﬂy, cells were ﬁxed with a 3.7%
buffered formaldehyde solution for 7min, washed with PBS, permeabilized with
100% methanol for 20min and then washed twice with PBS. Samples were digested
with proteinase K for 15min, and then quenched with 3% hydrogen peroxide.
Samples were then washed with distilled water, labelled with deoxynucleotidyl
transferase at 37 C for 90min and then treated with stop buffer. The cells were
incubated with TACS-Sapphire substrate, and the colorimetric reaction was stop-
ped with 0.2N HCl after 30min. Absorbance was measured with a microplate
reader at 450 nm. The results are shown as mean±s.d. calculated from three
independent experiments.
Annexin V-FITC staining. To assess the extent of apoptosis after DNA damage,
cells were stained with both Annexin V-ﬂuorescein isothiocyanate (FITC) and
propidium iodide using the ApoScan Annexin V-FITC Apoptosis Detection Kit
(BioBud, Korea) according to the manufacturer’s protocol. Alternatively, cells were
ﬁxed in 70% (v/v) ethanol and stained with a solution containing RNase A
(50 mgml 1) and propidium iodide (50 mgml 1).
Adenoviruses and lentiviral shRNAs. For stable knockdown of PDCD5 gene
expression, two pairs of oligonucleotides (50-CCGGUGAUGAAGAUGACGA
UUAUUGCUCGAGCAAUAAUCGUCAUCUUCAUCAUUUUG-30) that
encoded the shRNA against each target MISSION shRNA were purchased (Sigma-
Aldrich). To generate lentiviral particles, pLKO.1-PURO PDCD5 plasmid with
three plasmids (pMDLg/pRRE, envelope pRSV-REV and pMD2.G) were co-
transfected using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) in
293FT cell line. After 48 h incubation, supernatants were collected and ﬁltered
using a 0.45-mm pore. HCT-116 line was then infected with lentivirus particles.
After incubation with virus supernatant for 2 days, cells were selected with
1 mgml 1 of puromycin (Sigma-Aldrich). Lentivirus PURO shRNA was generated
as a control. Recombinant adenoviruses expressing GFP and Cre recombinase were
generated as described43. These were constructed into an E1 shuttle vector, and
then linearized with PmeI. The linearized vector was cotransformed into E. coli BJ
5,183 along with pAdEasy1 vector. All viruses were propagated in 293A cells and
puriﬁed by CsCl density puriﬁcation. Viral particles were calculated at 260 nm
absorbance. The multiplicity of infection was calculated from viral particle
numbers44.
Cell fractionation. Cells were cultured on 100-mm plates and washed twice with
ice-cold PBS. Harvested cells were homogenized in buffer A (250mM sucrose,
10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 1mM DTT, 0.1mM
phenylmethylsulphonyl ﬂuoride, 20mM HEPES (pH 7.5) and protease inhibitor
cocktail (Roche)) using a Teﬂon pestle (Thomas Scientiﬁc) and then centrifuged at
1,000g at 4 C for 10min. Pellets were used as nuclear fractions while post-nuclear
supernatant fractions were centrifuged at 10,000g at 4 C for 10min to obtain
mitochondria. The pellets containing mitochondria were washed with buffer A and
resuspended in TXIP-1 buffer (1% Triton X-100, 150mM NaCl, 0.5mM EDTA
and 50mM Tris-HCl (pH 7.4)) containing a protease inhibitor cocktail. The post-
mitochondrial supernatant was centrifuged for 30min at 100,000g to obtain
cytosolic protein fractions.
Immunoﬂuorescence staining. Cells were cultured on coverslips. Cells were ﬁxed
in 4% paraformaldehyde for 30min at 4 C, and then treated with 0.4% Triton
X-100 in PBS for 10min at room temperature. For detection of endogenous
HDAC3, cells were incubated with anti-HDAC3 antibody at 37 C for 2 h, and then
stained with goat anti-rabbit rhodamine (Invitrogen) at 37 C for 1.5 h. DNA was
revealed with Hoechst 33258 staining. Cells were imaged using a confocal
microscope.
Statistical analysis. Statistical analyses were performed using a Student’s t-test
with Bonferroni correction for multiple comparisons. A P value of less than 0.05
was considered statistically signiﬁcant.
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